Athenex (ATNX) Hits New 1-Year Low at $13.04

Share on StockTwits

Athenex Inc (NASDAQ:ATNX) shares hit a new 52-week low during trading on Friday . The stock traded as low as $13.04 and last traded at $13.20, with a volume of 11888 shares traded. The stock had previously closed at $13.52.

Several research analysts recently commented on ATNX shares. ValuEngine cut shares of Athenex from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. BidaskClub cut shares of Athenex from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. Finally, Zacks Investment Research cut shares of Athenex from a “hold” rating to a “sell” rating in a report on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.75.

The firm has a market capitalization of $941.28 million, a P/E ratio of -5.79 and a beta of -1.67.

Athenex (NASDAQ:ATNX) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). The firm had revenue of $11.57 million during the quarter. Athenex had a negative net margin of 122.29% and a negative return on equity of 73.37%. Equities analysts predict that Athenex Inc will post -2 earnings per share for the current year.

In other Athenex news, Director Song-Yi Zhang sold 102,734 shares of the stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $17.24, for a total value of $1,771,134.16. Following the completion of the sale, the director now owns 4,000 shares in the company, valued at $68,960. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jinn Wu purchased 5,000 shares of the business’s stock in a transaction on Monday, August 20th. The stock was purchased at an average price of $17.20 per share, with a total value of $86,000.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at $68,800. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 27,000 shares of company stock valued at $405,120 and sold 344,317 shares valued at $5,859,972. Company insiders own 29.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of Athenex by 426.5% during the 1st quarter. Barclays PLC now owns 5,913 shares of the company’s stock worth $100,000 after buying an additional 4,790 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Athenex by 363.2% during the 2nd quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after buying an additional 5,434 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Athenex during the 1st quarter worth about $208,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Athenex during the 2nd quarter worth about $266,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Athenex during the 1st quarter worth about $289,000. Institutional investors own 19.83% of the company’s stock.

About Athenex (NASDAQ:ATNX)

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Further Reading: Outstanding Shares

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Tricon Capital Group  Hits New 52-Week Low at $9.91
Tricon Capital Group Hits New 52-Week Low at $9.91
ProShares UltraPro Short Dow30  Trading Up 3.1%
ProShares UltraPro Short Dow30 Trading Up 3.1%
WABCO Holdings Inc.  Receives $131.80 Average PT from Analysts
WABCO Holdings Inc. Receives $131.80 Average PT from Analysts
Zacks: Analysts Expect Interface, Inc.  Will Post Quarterly Sales of $344.82 Million
Zacks: Analysts Expect Interface, Inc. Will Post Quarterly Sales of $344.82 Million
Invictus Hyperion Fund  Price Hits $0.0196 on Major Exchanges
Invictus Hyperion Fund Price Hits $0.0196 on Major Exchanges
Noah Malone Mitchell III Purchases 77,940 Shares of TransAtlantic Petroleum Ltd  Stock
Noah Malone Mitchell III Purchases 77,940 Shares of TransAtlantic Petroleum Ltd Stock


© 2006-2018 Ticker Report